NCI’s Consumer Liaison Group Chooses Four Areas of Concern

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

BETHESDA, Md--The new consumer liaison group to the NCI director has chosen three of its 15 members to serve as co-chairs and has identified four areas of concern for its initial attention.

BETHESDA, Md--The new consumer liaison group to the NCI director has chosen three of its 15 members to serve as co-chairs and has identified four areas of concern for its initial attention.

The co-chairs are M. Venus Gines, a breast-cancer survivor from Lithonia, Ga, active in community work with the American Cancer Society; Susan A. Leigh of Tucson, Ariz, a survivor of Hodgkin’s disease, breast cancer, and bladder cancer, and active in the National Coalition for Cancer Survivorship and the Oncology Nursing Society; and Daniel M. Moore, Jr., a prostate cancer survivor from Decatur, Ill, who started the Central Illinois US TOO! prostate cancer support group.

The consumer group’s four areas of immediate concern are communications and immediate access to reliable cancer information; informed consent, including making forms more understandable; patient consumer issues and population and genetics studies; and ways to identify additional consumer representatives for NCI committees and groups.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content